Trial reportThe Journal of dermatology2026
Exploratory MRI and Clinical Marker Analysis of Pustulotic Arthro-Osteitis Disease Activity From a Phase 3 Brodalumab Trial.
Trial report in The Journal of dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04061252 (A Phase 3, Placebo-Controlled, Double-Blind Comparative Study of KHK4827 With an Open-Label Extension in Subjects With Palmoplantar Pustulosis), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 3, Placebo-Controlled, Double-Blind Comparative Study of KHK4827 With an Open-Label Extension in Subjects With Palmoplantar Pustulosis
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Pustulotic arthro-osteitis (PAO) is a clinically important osteoarticular comorbidity affecting approximately 9%-28% of patients with palmoplantar pustulosis (PPP), yet early recognition and standardized activity assessment remain challenging, particularly in routine dermatology practice. This exploratory analysis evaluated patients with PAO to identify potential indicators of disease activity. A magnetic resonance imaging (MRI)-based scoring system for the anterior chest wall (ACW) in patients with PAO was developed. This post hoc analysis used data from the PAO subgroup of patients with PPP enrolled in a previous phase 3 trial. Correlations were assessed between clinical indicators-Ankylosing Spondylitis Disease Activity Score, Assessment of SpondyloArthritis international Society Health Index score, physicians' Numeric Rating Scale-PAO (NRS-PAO) activity score, and patients' NRS-PAO pain score-and MRI indicators, including active lesions such as bone marrow edema extent and intensity, and structural lesions in the ACW, spine, and sacroiliac joints (Spondyloarthritis Research Consortium of Canada [SPARCC] score); the correlations between MRI indicators and plain radiographic indicators were also evaluated. Of 20 included patients (mean age: 56.6 years), the majority were female. MRI examinations detected bone marrow edema in all patients. None of the clinical indicators showed a clear association with MRI indicators. There was no clear association between radiographic indicators and the bone marrow edema extent or intensity scores of lesions in the ACW. The spine SPARCC score was positively correlated with the osteosclerosis score of the ACW (|r| = 0.70; p = 0.0218) and the modified Stoke Ankylosing Spondylitis Spinal Score of the spine (|r| = 0.93; p < 0.001). The MRI-based ACW scoring system may provide a feasible method to standardize disease activity assessment in PAO in clinical practice. Further external validation is warranted, and additional clinical indicators are needed to predict disease activity. Trial Registration: NCT04061252, UMIN000055398.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.